New gene testing technology finds cancer risks 'hiding in plain sight' Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, April 29, 2016

New gene testing technology finds cancer risks 'hiding in plain sight'

Science news

 "When a woman with a family history of breast cancer sees her physician, they want to know if they have a mutation in breast/ovarian cancer genes," says Rogan. "All of the patients that we studied had been sequenced for BRCA1 or BRCA2. The causative cancer gene variants are hiding in plain sight in these and other cancer genes, but the original testing laboratory didn't recognize them. Our approach can reveal gene variants that might explain their increased risk for cancer."

Journal References:
  1. Eliseos J. Mucaki, Natasha G. Caminsky, Ami M. Perri, Ruipeng Lu, Alain Laederach, Matthew Halvorsen, Joan H. M. Knoll, Peter K. Rogan. A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer. BMC Medical Genomics, 2016; 9 (1) DOI: 10.1186/s12920-016-0178-5
  2. Natasha G. Caminsky, Eliseos J. Mucaki, Ami M. Perri, Ruipeng Lu, Joan H.M. Knoll, Peter K. Rogan. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer (HBOC) Genes in Patients Lacking knownBRCAMutations. Human Mutation, 2016; DOI: 10.1002/humu.22972


Post a Comment

Your comments?